MEET THE TEAM

Our Leadership Team and Board of Directors have extensive, proven experience in product development, clinical trials, regulatory affairs, business and commercial development, finance, and intellectual property management.

Founder, President,
Chief Executive Officer:
A physician-scientist, Dr. Niklason’s groundbreaking work in vascular and lung engineering has made her a world leader in regenerative medicine. She is a member of the National Academies of Engineering and Medicine, and serves on the advisory board of Trestle Biotherapeutics.

Chief Financial Officer, Chief Corporate Development Officer, Treasurer:
Mr. Sander has served as Chief Financial Officer of six other life science companies during both private and public phases, including two companies dual-listed in the U.S. and international markets.

Chief Operating Officer:
Dr. Prichard’s overall responsibility is translating the company’s innovative mission, vision and strategies into actionable activities. She brings over 20 years of strong leadership experience in the fields of tissue engineering, extracellular matrix biology, and biological response to implantable biomaterials.

Chief Medical Officer:
Dr. Parikh is an experienced medical professional with nearly two decades of biopharmaceutical experience leading teams across Clinical Strategy and Development, Medical Affairs and Patient Safety. After receiving his medical degree from the Topiwala National Medical College in Mumbai, India, he completed his post-graduate training in the US in internal medicine and pediatrics, followed by a clinical fellowship in endocrinology at the NIH.

Co-Founder, Executive Vice President Corporate Development:
Dr. Blum has spent over 20 years combining her scientific technical expertise with bioengineered tissue development to build Humacyte’s novel biotechnology platform and bring potential therapeutic products to market. Her leadership focuses on pairing the strategic direction of the organization with the overall corporate communications and culture of the business.

Chief Commercial Officer:
Mr. Scheessele is a commercial leader with over 20 years of experience creating and growing businesses in the vascular and regenerative medicine markets. He is responsible for providing leadership, direction, and strategic vision to drive the commercial launch of the HAV in its initial vascular indications and follow-on market expansion.

Chief Regulatory Officer:
Cindy Cao, Ph.D., has over twenty years of drug discovery and development experience in pharmaceutical and biotech companies and has extensive expertise in global and US regulatory strategy and policy on biologics. Dr. Cao holds a B.S. in Genetics from Fudan University, a Ph.D. in Biomedical Sciences from the University of New Mexico, and completed an NIH-sponsored post-doctoral fellowship at the University of Utah.

Executive Vice President, Business Strategy & People:
Ms. Osborne has over 20 years of Human Resources, Leadership, and Organizational Development experience across Life Sciences industry. Osborne’s management experience inside and outside of the Human Resources function provides for the ability to balance business needs with management and people needs to expertly craft and implement People strategies that ensure successful business outcomes.

Senior VP of Quality:
Mr. Alterson has over 20 years’ experience in the biopharmaceutical, vaccine, and cell/gene therapy industries while working at both clinical stage and commercial stage companies in roles of increasing responsibility across both Quality Control and Quality Assurance.  He has led multiple successful health authority inspections including PAIs.  

Senior Executive Regulatory Strategic Advisor:
Mr. Tente has over 30 years of experience in the process development and manufacturing of biotherapeutic products as well as cell, gene and tissue engineering therapies for research-stage and clinical-stage companies. Tente has led teams involved with the translation of academic biomedical research to large-scale manufacturing under FDA Good Manufacturing Practices compliance.

A physician-scientist, Dr. Niklason’s groundbreaking work in vascular and lung engineering has made her a world leader in regenerative medicine. She is a member of the National Academies of Engineering and Medicine and serves on the advisory board of Trestle Biotherapeutics.

Laura E. Niklason, M.D., Ph.D.

Founder, President,
Chief Executive Officer

Mr. Sander has served as Chief Financial Officer of six other life science companies during both private and public phases, including two companies dual-listed in the U.S. and international markets.

Dale Sander

Chief Financial Officer, Chief Corporate Development Officer, Treasurer

Dr. Prichard's overall responsibility is translating the company’s innovative mission, vision and strategies into actionable activities. She brings over 20 years of strong leadership experience in the fields of tissue engineering, extracellular matrix biology, and biological response to implantable biomaterials.

Heather Prichard, Ph.D.

Chief Operating Officer

Dr. Parikh is an experienced medical professional with nearly two decades of biopharmaceutical experience leading teams across Clinical Strategy and Development, Medical Affairs, and Patient Safety. After receiving his medical degree from the Topiwala National Medical College in Mumbai, India, he completed his post-graduate training in the US in internal medicine and pediatrics, followed by a clinical fellowship in endocrinology at the NIH.

Shamik Parikh, M.D.

Chief Medical Officer
Dr. Blum has spent over 20 years combining her scientific technical expertise with bioengineered tissue development to build Humacyte’s novel biotechnology platform and bring potential therapeutic products to market. Her leadership focuses on pairing the strategic direction of the organization with the overall corporate communications and culture of the business.

Juliana L. Blum, Ph.D.

Co-Founder,
Executive Vice President Corporate Development

Mr. Scheessele is a commercial leader with over 20 years of experience creating and growing businesses in the vascular and regenerative medicine markets. He is responsible for providing leadership, direction, and strategic vision to drive the commercial launch of the HAV in its initial vascular indications and follow-on market expansion.

BJ Scheessele

Chief Commercial Officer

Cindy Cao, Ph.D., has over twenty years of drug discovery and development experience in pharmaceutical and biotech companies and has extensive expertise in global and US regulatory strategy and policy on biologics. Dr. Cao holds a B.S. in Genetics from Fudan University, a Ph.D. in Biomedical Sciences from the University of New Mexico, and completed an NIH-sponsored post-doctoral fellowship at the University of Utah.

Cindy Cao, Ph.D. ​

Chief Regulatory Officer

Ms. Osborne has over 20 years of Human Resources, Leadership, and Organizational Development experience across Life Sciences industry. Osborne’s management experience inside and outside of the Human Resources function provides for the ability to balance business needs with management and people needs to expertly craft and implement People strategies that ensure successful business outcomes.

Sabrina Osborne

Executive Vice President,
Business Strategy & People

Mr. Alterson has over 20 years’ experience in the biopharmaceutical, vaccine, and cell/gene therapy industries while working at both clinical stage and commercial stage companies in roles of increasing responsibility across both Quality Control and Quality Assurance. He has led multiple successful health authority inspections including PAIs.

Harold Alterson

Senior VP of Quality


Mr. Tente has over 30 years of experience in the process development and manufacturing of biotherapeutic products as well as cell, gene and tissue engineering therapies for research-stage and clinical-stage companies. Tente has led teams involved with the translation of academic biomedical research to large-scale manufacturing under FDA Good Manufacturing Practices compliance.

William Tente, M.S. ​

Senior Executive Regulatory Strategic Advisor

 

 

History Defining Milestones

Board of Directors

Kathleen Sebelius

Chair of the Board

Ms. Sebelius has served as a member of the Humacyte Board since September 2015. From April 2009 to June 2014, Ms. Sebelius served as Secretary of the Department of Health and Human Services, or HHS. Sebelius holds a Master of Public Administration degree from the University of Kansas and a B.A. in Political Science from Trinity Washington University. Ms. Sebelius serves as the Chair of Humacyte’s Board of Directors.

Gordon M. Binder

Mr. Binder served as the Chief Executive Officer of Amgen, Inc. from 1998 through 2000.  He is a fellow of the American Academy of Arts and Sciences and is the author of Science Lessons: What the Business of Biotech Taught Me About Management. Mr. Binder holds a B.S. in Electrical Engineering from Purdue University and an M.B.A. from Harvard Business School, where he was a Baker Scholar.

Emery N. Brown, M.D., Ph.D.

Dr. Brown is a member of the National Academy of Inventors, the National Academy of Medicine, the National Academy of Sciences and the National Academy of Engineering. Dr. Brown holds an M.D. from Harvard Medical School, a Ph.D. and M.A. in Statistics from Harvard University, and a B.A. in Applied Mathematics from Harvard College.

Michael T. Constantino

Mr. Constantino is a retired Ernst & Young LLP assurance partner who served in the Research Triangle Park region of North Carolina for over 30 years. Mr. Constantino holds a B.A. in both Accounting and Business Management from NC State University and is a North Carolina Certified Public Accountant, or CPA. Mr. Constantino is serves as Chair of Humacyte’s Audit Committee.

Brady W. Dougan

Mr. Dougan served as the chair of the Humacyte Board from March 2019 to August 2021, and as a member of its Board of Directors since 2005. Mr. Dougan holds a B.A. in Economics and an M.B.A. in Finance from the University of Chicago. Mr. Dougan has been a member of Humacyte’s Board since the Company’s founding.

C. Bruce Green, M.D.

Dr. Green is a family physician who served as the 20th Surgeon General of the U.S. Air Force where he oversaw a $6B budget and 42,000 U.S. Air Force Medical Service personnel. During his 34-year Air Force career, he commanded 4 hospitals including the largest AF Medical Center. Dr. Green received his M.D. from the Medical College of Wisconsin, and his M.P.H. from the Harvard School of Public Health.  Retiring from the U.S. Air Force as a Lieutenant General in 2012, he served as Director and Chief Federal Medical Officer of Deloitte Consulting for nearly 10 years and is now an independent consultant.

Laura E. Niklason, M.D., Ph.D.

Dr. Niklason is the founder of Humacyte and has served as President and Chief Executive Officer since November 2020 and as a member of the Humacyte Board since 2004. Dr. Niklason holds a Ph.D. in Biophysics from the University of Chicago and an M.D. from the University of Michigan. Dr. Niklason has been a member of Humacyte’s Board since the Company’s founding.

Todd M. Pope

Mr. Pope has served as the President and Chief Executive Officer of WellAir Group Ltd., a leading clean air solutions company, since February 2021. He also previously served as worldwide president of Cordis, a multi-billion-dollar division within Johnson & Johnson’s medical device business. Time Magazine named Mr. Pope one of the “50 most influential people in healthcare 2018.” Mr. Pope holds a B.A. in Labor and Industrial Relations from the University of North Carolina.

Diane Seimetz, Ph.D.

Dr. Seimetz has over 22 years of international drug development, partnering and managerial experience in the biopharmaceutical industry. In 2013, she co-founded Biopharma Excellence, serving as Chief Executive Officer until June 2021. Dr. Seimetz received a degree in Pharmaceutical Science from the University of Saarland, a Master’s degree in Drug Regulatory Affairs from the University of Bonn, and a Ph.D. from the University of Heidelberg.

Rajiv Shukla

Mr. Shukla has served as AHAC’s Chairman and Chief Executive Officer since inception and has two decades of buyouts, investments and operations experience in the healthcare industry. He served as Chairman and Chief Executive Officer of CNAC, successfully closing its initial business combination with DermTech. Mr. Shukla holds a Masters in Healthcare Management and Policy from Harvard University and a Bachelors in Pharmaceutics from the Indian Institute of Technology.

Max Wallace, J.D.

Mr. Wallace served as Chief Executive Officer of Accelerate Brain Cancer Cure, or ABC, a not-for-profit corporation seeking to drive research and treatments for brain tumors, from August 2008 to December 2019. Mr. Wallace holds a B.A. in English and Political Science from Duke University and a J.D. from the University of Florida. Mr. Wallace has been a member of Humacyte’s Board since the Company’s founding.

Susan Windham-Bannister, Ph.D.

Dr. Windham-Bannister has served as President and Chief Executive Officer of Biomedical Growth Strategies, LLC, a strategic advisory firm serving the life sciences and healthcare industries, since September 2015. Dr. Windham-Bannister holds a Ph.D. in Health Policy and Management from the Florence Heller School at Brandeis University.

Partnerships

Scroll to Top